1. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: Strategic considerations;Gabrielsson J;Drug Discov Today.,2009
2. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain fv constructs;Davda JP;Int Immunopharmacol.,2008
3. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice;Baxter LT;Cancer Res.,1994
4. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies;Zhu H;J Nucl Med.,1997